Targeted therapeutics designed to address unmet needs in immune-mediated diseases
We have a robust pipeline of therapeutic development programs to address several clinical IBD patient subpopulations, and plan to develop a companion diagnostic for each program.
Prometheus Biosciences therapeutic pipeline
| Program | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| PRA023 TL1A mAb | Ulcerative Colitis | ||||
| Crohn's Disease | |||||
| SSc-ILD | |||||
| PRA052* CD30 ligand mAb | Immune-Mediated Diseases | ||||
| PR1100 Cytokine receptor mAb | Immune-Mediated Diseases | ||||
| PR2100 Inflammatory cytokine mAb | Immune-Mediated Diseases | ||||
| PR300 GPCR small molecule | Immune-Mediated Diseases | ||||
*Partnered with Dr. Falk Pharma in Europe, Australia, and New Zealand
Strategic collaborations and partnerships
To advance our game-changing precision medicines platform, we have forged partnerships with pharmaceutical companies, foundations, and academic groups with critical gastrointestinal (GI) area expertise and resources. This approach has accelerated the application of our technology and enabled us to secure necessary funding to advance our development progress.
Our partners include Cedars-Sinai Medical Center, University of California San Diego, and Dr. Falk Pharma GmbH.
Partnership inquiries
We strive to be the partner of choice in gastrointestinal (GI) and immune-mediated diseases by applying our technology and utilizing the Prometheus360™ platform to advance clinical programs. For inquiries or to learn more, please contact us.
Prometheus Biosciences
844-306-0547
3050 Science Park Rd.
San Diego, CA 92121
BD@prometheusbiosciences.com